Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. (US RLD: Rytary®)
This combination medication is indicated for the treatment of Parkinson’s disease or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving) and will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.252.8 as compared to the previous close of Rs. 256.7. The total number of shares traded during the day was 78231 in over 2788 trades.
The stock hit an intraday high of Rs. 265 and intraday low of 248. The net turnover during the day was Rs. 20011030.-Equity Bulls